Investors expect a home run now; earnings beat may not suffice
24/10/25 -"The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by Dupixent and the recent years’ new ..."
Pages
67
Language
English
Published on
24/10/25
You may also be interested by these reports :
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...
23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...
22/10/25
Ipsen’s Q3 sales surpassed expectations, showing robust growth across all segments. Consequently, the 2025 guidance has been revised upwards. The ...